4.7 Article

Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries

期刊

AMERICAN JOURNAL OF CHINESE MEDICINE
卷 49, 期 3, 页码 543-575

出版社

WORLD SCIENTIFIC PUBL CO PTE LTD
DOI: 10.1142/S0192415X21500257

关键词

Coronavirus Disease 2019; COVID-19; Integrative Medicine; Chinese Medicine; Cohort; Effectiveness; Mortality

资金

  1. National Key Research and Development Program [2017YFC1703506, 2020YFC0841600]
  2. Beijing Natural Science Foundation [M21012]

向作者/读者索取更多资源

The study evaluated the real-world effectiveness of add-on semi-individualized Chinese medicine (CM) in treating COVID-19 during the outbreak, and found that it significantly reduced mortality among COVID-19 patients, especially in severe/critical cases. Immune-modulating and anti-asthmatic CMs were commonly used, and the effects were dose-dependent.
Chinese medicine (CM) was extensively used to treat COVID-19 in China. We aimed to evaluate the real-world effectiveness of add-on semi-individualized CM during the outbreak. A retrospective cohort of 1788 adult confirmed COVID-19 patients were recruited from 2235 consecutive linked records retrieved from five hospitals in Wuhan during 15 January to 13 March 2020. The mortality of add-on semi-individualized CM users and non-users was compared by inverse probability weighted hazard ratio (HR) and by propensity score matching. Change of biomarkers was compared between groups, and the frequency of CMs used was analyzed. Subgroup analysis was performed to stratify disease severity and dose of CM exposure. The crude mortality was 3.8% in the semi-individualized CM user group and 17.0% among the non-users. Add-on CM was associated with a mortality reduction of 58% (HR = 0.42, 95% CI: 0.23 to 0.77, p = 0.005) among all COVID-19 cases and 66% (HR = 0.34, 95% CI: 0.15 to 0.76, p = 0.009) among severe/critical COVID-19 cases demonstrating dose-dependent response, after inversely weighted with propensity score. The result was robust in various stratified, weighted, matched, adjusted and sensitivity analyses. Severe/critical patients that received add-on CM had a trend of stabilized D-dimer level after 3-7 days of admission when compared to baseline. Immunomodulating and anti-asthmatic CMs were most used. Add-on semi-individualized CM was associated with significantly reduced mortality, especially among severe/critical cases. Chinese medicine could be considered as an add-on regimen for trial use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据